Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Atai Beckley Inc.NASDAQ: ATAI

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital turns negative

Q2 FY2026 change in working capital was -$2.83M, compared with $7.8M a year earlier. Trailing-twelve-month change in working capital was -$13.78M. Over 3 fiscal years it compounded at +24.8% a year.

Context

  • Change in working capital amounted to 158.4% of revenue in FY2025, down 2828.7 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near -$2.83M or moves back toward the trailing-twelve-month quarterly average of -$3.44M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.83M-240.1% QoQ
Last fiscal yearDec 2025
-$6.48M-29.6% YoY
LTMJun 2026
-$13.78M+1200.4% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-136.2%——
1 year-29.6%——
3-year CAGR+24.8%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(6.48M) USD
Year-over-year change
+29.6%

Change in Working Capital vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1200.4% is the highest of 11, against a peer median of +76.6%.
  • Change in working capital amounts to 308.0% of revenue for ATAI, versus a peer median of 200.2%.
ATAI Competitors
Change in Working Capital for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$80.94M USD-757.4%—37.3%
NKTRNektar TherapeuticsLTM Jun 2026$79.97M USD+464.0%—146.5%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$26.29M USD+172.3%—254.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$19.93M USD-141.4%—1532.9%
IMTXImmatics N.V.LTM Mar 2026€14.05M EUR-90.7%—37.7%
ATAIAtai Beckley Inc.LTM Jun 2026$13.78M USD+1200.4%+24.8%308.0%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$12.54M USD+251.7%—658.7%
SANASana Biotechnology, Inc.LTM Mar 2026$6.99M USD+52.5%——
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$1.22M USD+142.8%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$974K USD-159.1%+130.6%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$183K USD+100.7%-12.9%—
Peer median (excluding ATAI) —+76.6%+58.8%200.2%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.